

# Nephrology



## Coordinator

Ballarín Castán, José F. Puigvert  
jballarin@fundacio-puigvert.es

## Members

Ars Criach, Elisabeth F. Puigvert  
Bardají de Quixano, Beatriz F. Puigvert  
Bover Sanjuan, Jordi F. Puigvert  
Bullich Vilanova, Gemma F. Puigvert  
Coll Piera, Elisabet F. Puigvert  
Da Silva Santos, Iara Karlla F. Puigvert  
Díaz Encarnación, Montserrat Mercedes F. Puigvert  
Díaz Gómez, Joan Manel F. Puigvert  
Fernández de la Llama, Patricia F. Puigvert  
Furlano, Mónica María F. Puigvert  
Gràcia García, Silvia F. Puigvert  
Guillén Gómez, Elena F. Puigvert  
Guirado Perich, Lluís F. Puigvert  
Lorente Grandoso, Laura F. Puigvert  
Sanmiguel Amigo, Luz F. Puigvert  
Silva Torres, Irene F. Puigvert  
Torra Balcells, Roser F. Puigvert

## Main Lines of Research

Fundació Puigvert's Nephrology Research Group has been part of the IIB since its very beginning. The group carries out translational research within the field of renal diseases along different lines from hypertension, hereditary diseases, glomerular diseases and renal fibrosis, to transplants and dialysis.

Those different lines are analysed in detail below:

- ▶ Dra. Torra is the head researcher of the hereditary diseases line she and Dra. Ars have led many research projects on these diseases, and both have supervised several doctoral theses. The hereditary renal diseases team is currently analysing phenotype variability of those diseases, both in its genomic and its clinical dimension. Dra. Torra coordinates both the Catalan and the Spanish hereditary renal diseases teams, and is a member of the homonymous European board of the EDTA (European Dialysis and Transplant Association).
- ▶ Dra. Ars heads the molecular genetics laboratory; she has optimised the Next generation sequencing tools for hereditary renal diseases, in collaboration with Dra. Gemma Bullich. Dra. Ars coordinates the Sant Pau IIB's Fundació Puigvert's On-line Biobank node belonging to the National Biobanks Platform. She is also the person responsible for organising an European Molecular Quality Network (EMQN) outline for quality control of the genetic diagnoses of ADPKD by European laboratories. Currently she is leading a research project for applying this outline to kidney and urinary tract congenital abnormalities.
- ▶ Jointly with Dra. Díaz, Dr. Ballarín leads a series of clinical trials, both national and international, on glomerular and systemic diseases affecting the kidneys. They also participate in registries at a Catalan, Spanish and European level.
- ▶ Dra. Díaz leads the studies on renal inflammation and fibrosis. Renal grafts from cadaveric donors are an apt model for her study due to their less-good prognosis and to a high probability of inflammation and ensuing fibrosis as compared to living donor grafts. Dra. Díaz and Dra. Guillén have identified the activation of purinoma elements, both in cell cultures and in grafts from cadaver donors. This activation participates in inflammation and fibrosis, triggered by the phenotype change of macrophages into anti-inflammatory and pro-fibrotic, and interacting with other pro-fibrotic classical pathways. This new role of the purinergic pathways could be the key for the detection of new markers and new therapeutic targets associated with renal graft dysfunction after transplant.
- ▶ Dra. Fernández-Llama is participating in the development of a prototype of a multiplex system for flow cytometry focused on a new multi-parametric etio-pathogenic diagnosis of acute renal damage. As an expert in hypertension, she participates in a collaborative trial for evaluating 24-hour central blood pressure, its circadian rhythms and its relationship with organic damage.
- ▶ Dr. Bover is also a member of the EDTA work force board on bone metabolism, this being his primary research subject.
- ▶ Dr. Díaz leads the dialysis research line. Currently the two major research lines are concerned with the appropriateness of peritoneal dialysis, and the investigation for biomarkers of the acute renal failure.
- ▶ Dra. Coll, who belongs in the dialysis team, heads the research of genomic damage in patients on renal replacement therapy, either transplant or dialysis. She analyses the differences of oxidative stress in transplanted vs. dialysis patients. She also analyses the effect of different antioxidants on genomic damage of dialysis patients.
- ▶ The transplant team, led by Dr. Guirado, either participates or heads over 15 studies, amongst them clinical trials with drugs against kidney rejection or for treating associated viral infections. His active participation and his leadership in the investigation of biochemical, serologic and genomic biomarkers of both rejection and viral infections associated with renal transplant, are outstanding.
- ▶ Ms. Luz San Miguel and Ms. Judith Ballart are the coordinators of clinical studies and trials. Their work is essential and of the utmost importance for carrying out the high number of clinical trials performed by the group.

## Challenges

- ▶ Maintain the level of national and international publication.
- ▶ Continue with both clinical and basic research in all the previously described areas.
- ▶ Participate in the elaboration of clinical nephrology guidelines.
- ▶ Continue with active collection of research samples from CKD and transplant patients.
- ▶ Maintain participation in national working groups and increase international cooperation.
- ▶ Engage in new pharmaceutical clinical studies, including clinical trials.

## Collaborations

**Collaborations with other IIB Sant Pau Groups****Active collaborations in basic and clinical research projects**

- ▶ Inflammatory Diseases Group: renal fibrosis.
- ▶ Anaesthesiology Group (in collaboration with the Catalan ANES-CARDIOCAT Group): risk of major adverse cardiovascular and cerebrovascular events in non-cardiac surgery associated with the preoperative estimated glomerular filtration rate.
- ▶ Paediatrics Group: nephrotic syndrome evolution, Ig A nephropathy and inherited kidney diseases.
- ▶ Andrology Group: infertility.
- ▶ Urology Group: genetic predisposition to prostate cancer and transplant.
- ▶ Gynecology: High risk pregnancies, prenatal diagnosis, preimplantation diagnosis.
- ▶ Multidisciplinary teams for inherited kidney diseases: collaboration with most specialities from Sant Pau Hospital for different inherited kidney diseases (data bases, articles, protocols...)

**Platforms**

- ▶ Biobank platform.

**External Collaborations****National academic collaborations**

- ▶ Department of Biochemistry and Molecular Biology, Universitat de Barcelona, Institute of Biomedicine and Oncology Programme, National Biomedical Research Institute of Liver and Gastrointestinal Diseases (CIBER EHD): renal fibrosis.
- ▶ Laboratory of Proteomics CSIC/Universitat Autònoma de Barcelona: diabetic nephropathy.
- ▶ Mutagenesis Department of Universitat Autònoma de Barcelona: renal impairment in chronic kidney disease.
- ▶ Genomic Regulation Center (CRG): inherited kidney diseases.
- ▶ Universidad de Salamanca: acute kidney injury.
- ▶ Universitat de Lleida: chronic kidney disease.

- ▶ National Scientific Societies (such as Sociedad Española de Nefrología) and investigators of other centres: basic and clinical studies (including public grants, clinical trials, observational studies...) promoted by them.

**International academic collaborations**

- ▶ Biochemistry and Microbiology Institute UACH (Chile): renal fibrosis and diabetic nephropathy.
- ▶ Mayo Clinic (Rochester, USA): Autosomal Dominant Polycystic Kidney Disease (ADPKD).
- ▶ Hospital Tenon (Paris, France): Nephrotic syndrome.
- ▶ EURenOmics Platform: membranous nephropathy and nephrotic syndrome.
- ▶ Toronto General Hospital (Canada): molecular genetics of idiopathic nephrotic syndrome.
- ▶ University of Melbourne (Australia): Alport syndrome.
- ▶ University Medicine Goettingen (Germany): Alport syndrome.
- ▶ EDTA (multinational, Europe): inherited kidney diseases and chronic kidney disease-mineral and bone disorders.
- ▶ Addenbrooke's Hospital, Cambridge University Hospitals NHS (United Kingdom): vasculitis.
- ▶ EUVAS Group (multinational collaborative Group): vasculitis.

**Private national and international collaborations**

- ▶ Participation in clinical studies including clinical trials and post-authorisation studies promoted by national and international pharmaceutical companies.
- ▶ Research Joint-Venture with VU Medisch Centrum (Amsterdam, The Netherlands); Medizinische Klinik I (Aachen, Germany) and San Paolo Hospital (Milan, Italy) sponsored by Abbvie Co on effects of vitamina D derivatives in CKD-MBD.

**Other collaborations**

- ▶ tient organisations: inherited diseases (AIRG), lupus (ACLECA) and chronic kidney disease (ALCER).

# Nephrology

## Active Grants

- ▶ Roser Torra Balcells. Nefropatías familiares no filiadas: genes implicados en su causa y su variabilidad fenotípica.. PI15/01824. Instituto de Salud Carlos III. Duration: 2016-2018. 115,500.00 €.
- ▶ Elisabeth Ars Criach. Estudio genómico de nefropatías de inicio temprano.. PI16/01998. Instituto de Salud Carlos III. Duration: 2017-2019. 107,500.00 €.
- ▶ Elisabeth Ars Criach. Enfermedades renales hereditarias quísticas y glomerulares: secuenciación masiva de un panel de genes para mejorar su diagnóstico y del exoma para identificar nuevos genes.. PI13/01731. Instituto de Salud Carlos III. Duration: 2014-2017. 68,000.00 €.
- ▶ Lluís Guirado Perich. Estudi multicèntric, aleatoritzat per avaluar l'eficàcia de la individualització del risc immunològic basat en biomarcadors selectius (disparitat d'eplets HLA i ELISPOT IFN- $\gamma$ ), per optimitzar el tractament immunosupressor en pacients trasplantats renals de donant viu (BIOIMMUN). Generalitat de Catalunya PERIS 2016. SLT002/16/00089. Duration: 2017-2019. 30,589.14 €.
- ▶ José Ballarín Castán. Red de Investigación Renal. ISCIII. RD16/0009/0019. Duration: 2017-2020. 121,379.50 €.
- ▶ José Ballarín Castán. Grup d'Investigació en Nefrologia. AGAUR. 2017 SGR 676. Duration: 2017-2019.

Note: Total amount granted to PI. It does not include indirect costs.

## Grants Awarded in 2017

- ▶ Montserrat Mercedes Díaz Encarnación. Impacto de las vías purinérgicas sobre la activación de macrófagos en el donante cadáver: pieza clave en el desarrollo de fibrosis y disfunción en el trasplante renal. PI17/01566. Instituto de Salud Carlos III. Duration: 2018-2020. 44,000.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

## Theses

- ▶ Carme Facundo. Avaluació del filtrat glomerular en el donant viu renal. Universitat Autònoma de Barcelona. Director: Lluís Guirado. Date of defense: 30/10/2017.
- ▶ Nadia Ayasreh. Nefropatía tubulointerstitial autosómica dominante. Universitat Autònoma de Barcelona. Director: R. Torra and E. Ars. Date of defense: 02/06/2017.
- ▶ Cristina Canal. Supervivència d'empelt i pacient a llarg termini en el trasplantament renal a Catalunya. Universitat Autònoma de Barcelona. Director: Lluís Guirado. Date of defense: 13/12/2017.
- ▶ Helena Marco Rusiñol, El Rituximab como tratamiento en las enfermedades autoinmunes. Universitat Autònoma de Barcelona. Directors: J. Ballarín, D.Jayne, M. Díaz-Encarnación. Date of defense: 14/07/2017.

## Awards

- ▶ Dra R Torra. Recognition of research, clinical outreach and the spread of rare diseases and / or orphan drugs. Best clinical career. Madrid, 27th November. Award from the Asociación Española de Laboratorios de medicamentos huérfanos y ultrahuérfanos (AELMHU).

## Transfer Products

- ▶ "Talking about Dominant Kidney Poliquistosis. Patient and familiars information session". Direction: Dr J.Ballarín and ALCER Patient Association. Barcelona, 17th October.
- ▶ "Living with kidney disease (VI edition meeting for patients)". Direction: Dr J.Ballarín. Barcelona, 16th November.

## Other Publications

- ▶ Vincenti F., Fervenza FC, Campbell KN, Díaz M., Gesualdo L., Nelson P, Praga M., Radhakrishnan J., Sellin L., Singh A., Thornley-Brown D., Veronese FV., Accomando B., Engstrand S., Ledbetter S., Lin J., Neylan J., Tumlin J. A phase 2, double blind, placebo controlled, randomized study of fresolimumab in patients with steroid-resistant primary focal segmental glomerulosclerosis. (2017) *Kidney Int Rep* 2 5 800-810.

\*TIF: 155.648 \*\*MIF: 3,9909

Arroyo D., Betriu A., Valls J., Gorris J.L., Palares V., Abajo M., Gracia M., Valdivielso J.M., Fernandez E., Aladren Regidor M.J., et al. Factors influencing pathological ankle-brachial index values along the chronic kidney disease spectrum: The NEFRONA study (2017) NEPHROL DIAL TRANSPL, 32 (3), 513-520.

IF: 4.600

Ars E., Torra R. Rare diseases, rare presentations: recognizing atypical inherited kidney disease phenotypes in the age of genomics. (2017) clin kidney J 10 5 632-638.

IF: 4.470

Ayaresh N., Miquel R., Matamala A., Ars E., Torra R. Revisión de la nefropatía tubulointersticial autosómica dominante. (2017) NEFROLOGÍA 37 3 352-354.

IF: 1.167

Bover J., Bailone L., Lopez-Baez V., Benito S., Ciceri P., Galassi A., Cozzolino M., Osteoporosis, bone mineral density and CKD-MBD: treatment considerations (2017) J NEPHROL, 30 (5), 677-687.

IF: 2.724

Braun DA., Rao J., Mollet G., Shapiro D., Daugeron MC., Tan W., Gribouval O., Boyer O., Revy P., Furlano M., Mane S., Lifton RP., Bouchard M., Kannu P., Chitayat D., Magen D., Callewaert B., Van Tilbeurgh H., Zenker M., Antignac C., Hildebrandt F. Mutations in keops-complex genes cause nephrotic syndrome with primary microcephaly. (2017) NAT GENET 49, 10, 1529-1538.

IF: 27.125

Breda A., Territo A., Gausa L., Rodríguez-Faba O., Caffaratti J., de León P., Guirado L., Facundo C., Guazzieri M., Guttilla A., Villavicencio H. Robotic kidney transplantation: one year after the beginning. (2017) WORLD J UROL 35, 10, 1507-1515.

IF: 2.981

Bruj MJ., Marti T., Torra R., Villacampa F. Recommendations for imaging-based diagnosis and management of renal angiomyolipoma associated with tuberous sclerosis complex. (2017) CLIN KIDNEY J 10, 7, 728-737.

IF: 4.470

Bullich G., Vargas I., Trujillano D., Mendizabal S., Pinero-Fernandez J.A., Fraga G., Garcia-Solano J., Ballarin J., Estivill X., Torra R., Ars E., Contribution of the TTC21B gene to glomerular and cystic kidney diseases (2017) NEPHROL DIAL TRANSPL, 32 (1), 151-156.

IF: 4.600

Butragueño L., Ars E., Martínez López AB., Alvarez O., Tejado JJ., Luque de Pablos A. Alteración genética no descrita previamente en 2 pacientes pediátricos con síndrome de

Alport. Influencia pronóstica del genotipo. (2017) NEFROLOGÍA 37, 1, 87-92.

IF: 1.167

Carmona A., Agüera ML., Luna C., Buendia P., Calleros L., Garcia Jerez A., Rodriguez Puyol M., Arias M., De Arriba G., Ballarin J., Poch E., Portoles JM., Rodriguez Puyol D., Sanchez Villanueva R., Sarro F., Torres A., Martin Malo A., Aljama A., Ramirez P. Markers of endothelial damage in patients with chronic kidney disease on hemodialysis. (2017) AM J PHYSIOL RENAL PHYSIOL 312, 4, F673-F681.

IF: 3.164

Collado S., Coll E., Nicolau C., Azqueta M., Pons M., Cruzado J.M., De La Torre B., Deulofeu R., Mojal S., Pascual J., Cases A., Serum osteoprotegerin in prevalent hemodialysis patients: Associations with mortality, atherosclerosis and cardiac function (2017) BMC NEPHROL, 18 (1), -.

IF: 2.395

Corredor Z., Rodriguez-Ribera L., Coll E., Silva I., Diaz J.M., Ballarin J., Marcos R., Pastor S., DNA damage in kidney transplant patients. Role of organ origin (2017) ENVIRON MOL MUTAGEN, 58 (9), 712-718.

IF: 3.254

DaSilva I., Huerta A., Quintana L., Redondo B., Iglesias E., Draibe J., Praga M., Ballarin J., Diaz-Encarnacion M., Rituximab for Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome in Adults: A Retrospective, Multicenter Study in Spain (2017) BIODRUGS, 31 (3), 239-249.

IF: 3.825

David C., Bover J., Voiculet C., Peride I., Petcu L.C., Niculae A., Covic A., Checherita I.A., Coronary risk score for mineral bone disease in chronic non-diabetic hemodialysis patients: results from a prospective pilot study (2017) INT UROL NEPHROL, 49 (4), 689-700.

IF: 1.692

de la Sierra A., Pareja J., Fernandez-Llama P., Armario P., Yun S., Acosta E., Calero F., Vazquez S., Blanch P., Sierra C., Oliveras A., Twenty-four-hour central blood pressure is not better associated with hypertensive target organ damage than 24-h peripheral blood pressure (2017) J HYPERTENS, 35 (10), 2000-2005.

IF: 4.092

Dominguez-Gil B., Coll E., Elizalde J., Herrero J.E., Pont T., Quindos B., Marcelo B., Bodi M.A., Martinez A., Nebra A., Guerrero F., Mancino J.M., Galan J., Lebron M., Minambres E., Matesanz R., Expanding the Donor Pool Through Intensive Care to Facilitate Organ Donation: Results of a Spanish Multicenter Study (2017) TRANSPLANTATION, 101 (8), e265-e272.

IF: 3.960

Fernandez-Llama P., Pareja J., Yun S., Vazquez S., Oliveras A., Armario P., Blanch P., Calero F., Sierra C., de la Sierra A., Cuff-Based Oscillometric Central and Brachial Blood Pressures Obtained Through ABPM are Similarly Associated with Renal Organ Damage in Arterial Hypertension (2017) KIDNEY BLOOD PRESS R, 1068-1077.

IF: 3.000

Furlano M., Barreiro Y., Marti T., Facundo C., Ruiz-Garcia C., DaSilva I., Ayasreh N., Cabrera-Lopez C., Ballarin J., Ars E., Torra R., Renal angiomyolipoma bleeding in a patient with TSC2/PKD1 contiguous gene syndrome after 17 years of renal replacement therapy Sangrado de angiomiolipoma renal en paciente con síndrome de genes contiguos (TSC2/PKD1) tras 17 años de tratamiento renal sustitutivo (2017) NEFROLOGIA, 37 (1), 87-92.

IF: 1.167

Furlano M., Barreiro Y., Marti T., Facundo C., Ruiz-Garcia C., DaSilva I., Ayasreh N., Cabrera-Lopez C., Ballarin J., Ars E., Torra R., Renal angiomyolipoma bleeding in a patient with TSC2/PKD1 contiguous gene syndrome after 17 years of renal replacement therapy (2017) NEFROLOGIA, -.

IF: 1.167

Gross O., Kashtan C.E., Rheault M.N., Flinter F., Savige J., Miner J.H., Torra R., Ars E., Deltas C., Savva I., Perin L., Renieri A., Ariani F., Mari F., Baigent C., Judge P., Knebelman B., Heidet L., Lagas S., Blatt D., Ding J., Zhang Y., Gale D.P., Prunotto M., Xue Y., Schachter A.D., Morton L.C.G., Blem J., Huang M., Liu S., Vallee S., Renault D., Schifter J., Skelding J., Gear S., Friede T., Turner A.N., Lennon R., Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: Report from the 2015 International Workshop on Alport Syndrome (2017) NEPHROL DIAL TRANSPL, 32 (6), 916-924.

IF: 4.600

Guillen-Gomez E., Dasilva I., Silva I., Arce Y., Facundo C., Ars E., Breda A., Ortiz A., Guirado L., Ballarin J.A., Diaz-Encarnacion M.M., Early Macrophage Infiltration and Sustained Inflammation in Kidneys From Deceased Donors Are Associated With Long-Term Renal Function (2017) AM J TRANSPLANT, 17 (3), 733-743.

IF: 6.493

Kuebler B., Aran B., Miquel-Serra L., Munoz Y., Ars E., Bullich G., Furlano M., Torra R., Marti M., Veiga A., Raya A., Generation of integration-free induced pluripotent stem cell lines derived from two patients with X-linked Alport syndrome (XLAS) (2017) STEM CELL RES, 25, 291-295.

IF: 1.829

## Nephrology

\*TIF: 155.648 \*\*MIF: 3,9909

Kuebler B., Aran B., Miquel-Serra L., Munoz Y., Ars E., Bullich G., Furlano M., Torra R., Marti M., Veiga A., Raya A., Integration-free induced pluripotent stem cells derived from a patient with autosomal recessive Alport syndrome (ARAS) (2017) STEM CELL RES, 25, 1-5.

IF: 1.829

Macaya A., Torra, R. Recomendaciones para el abordaje multidisciplinar del complejo esclerosis tuberosa. Med Clin 2017, 149, 322.

IF:1.168

Massy, ZA; Nistor, I; Apertii, M; Brandenburg, VM; Bover, J; Evenepoel, P; Goldsmith, D; Mazzaferro, S; Ureña, P; Vervloet, M; Cozzolino, M; Covic, A. ERA-EDTA ob. Magnesium-based interventions for normal kidney function and chronic kidney disease. (2017) MAGNES RES 29, 4, 126-140.

IF: 1.281

Mateos Rodriguez A.A., Andres Belmonte A., Del Rio Gallegos F., Coll E., Factors affecting the survival of transplants from donors after prehospital cardiac death Factores que influyen en la evolución de los injertos de donantes tras muerte cardiaca extrahospitalaria (2017) EMERGENCIAS, 29 (3), 167-172.

IF: 3.608

Matesanz R., Dominguez-Gil B., Coll E., Mahillo B., Marazuela R., How Spain Reached 40 Deceased Organ Donors per Million Population (2017) AM J TRANSPLANT, 17 (6), 1447-1454.

IF: 6.493

Millan O., Budde K., Sommerer C., Aliart I., Rissling O., Bardaji B., Matz M., Zeier M., Silva I., Guirado L., Brunet M., Urinary miR-155-5p and CXCL10 as prognostic and predictive biomarkers of rejection, graft outcome and treatment response in kidney transplantation (2017) BRIT J CLIN PHARMACO, 83 (12), 2636-2650.

IF: 3.838

Molina P., Carrero J.J., Bover J., Chauveau P., Mazzaferro S., Torres P.U., Vitamin D, a modulator of musculoskeletal health in chronic kidney disease (2017) J CACHEXIA SARCO-PENI, 8 (5), 686-701.

IF: 12.511

Nube M.J., Peters S.A.E., Blankestijn P.J., Canaud B., Davenport A., Grooteman M.P.C., Asci G., Locatelli F., Maduell F., Morena M., et al., Mortality reduction by post-dilution on-line-haemodiafiltration: A cause-specific analysis (2017) NEPHROL DIAL TRANSPL, 32 (3), 548-555.

IF: 4.600

Pimentel A., Urena-Torres P., Zillikens M.C., Bover J., Cohen-Solal M., Fractures in patients with CKD—diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation (2017) KIDNEY INT, 92 (6), 1343-1355.

IF: 8.429

Rodriguez Faba O., Palou J., Vila Reyes H., Guirado L., Palazzetti A., Gontero P., Viguez F., Garcia-Olaverri J., Fernandez Gomez J.M., Olsburg J., Terrone C., Figueiredo A., Burgos J., Lledo E., Breda A., Treatment options and predictive factors for recurrence and cancer-specific mortality in bladder cancer after renal transplantation: A multi-institutional analysis Opciones terapéuticas y factores predictivos de recurrencia y mortalidad cáncer-específica en pacientes con tumor vesical después de trasplante renal: análisis multiinstitucional (2017) ACTAS UROL ESP, 41 (10), 639-645.

IF: 1.260

Rodriguez-Ribera L., Corredor Z., Silva I., Diaz J.M., Ballarin J., Marcos R., Pastor S., Coll E., Vitamin E-coated dialysis membranes reduce the levels of oxidative genetic damage in hemodialysis patients (2017) MUTAT RES-GEN TOX EN, 815, 16-21.

IF: 1.996

Rodríguez Ribera L., Pastor S., Corredor Z., Silva I., Díaz, JM., Ballarín J., Marcos R., Coll E. Genetic damage in patients moving from hemodialysis to online hemodiafiltration. (2017) MUTAGENESIS 31, 2 131-135.

IF: 2.507

Sandoval D., Poveda R., Draibe J., Perez Oller I., Diaz M., Ballarin J., Saurina A., Marco H., Bonet J., Barros X., Fulladosa X., Torras J., Cruzado JM. Efficacy of mycophenolate

treatment in adults with steroid-dependent/frequently relapsing idiopathic nephrotic syndrome. (2017) CLIN KIDNEY J 10, 5, 632-638.

IF: 4.470

Sans L., Radosevic A., Quintian C., Montanes R., Gracia S., Vilaplana C., Mojal S., Ballarin J.A., Fernandez-Llama P., Torra R., Pascual J., Cystatin C estimated glomerular filtration rate to assess renal function in early stages of autosomal dominant polycystic kidney disease (2017) PLOS ONE, 12 (3), -.

IF: 2.766

Tebe C., Arcos E., Comas J., Espallargues M., Pons JMV., Díaz JM., Tort J., Martínez-Castellao A. Atlas de variaciones sistemáticas en el tratamiento sustitutivo renal en Catalunya (2002-2012). (2017) NEFROLOGÍA 37, 2, 164-171.

IF:1,1830

Torres P.A.U., Bover J., Cohen-Solal M., Etelcalcetide: Injectable calcimimetic for the treatment of secondary hyperparathyroidism in hemodialysis-dependent patients (2017) DRUG TODAY, 53 (9), 489-500.

IF: 1.325

Vervloet M.G., Brandenburg V.M., Bover J., Brandenburg V., Covic A., Cozzolino M., Evenepoel P., Goldsmith D., Massy Z., Mazzaferro S., Urena-Torres P., Vervloet M., Circulating markers of bone turnover (2017) J NEPHROL, 30 (5), 663-670.

IF: 2.724

Wadström J, Ericzon BG, Halloran PF, Bechstein WO, Opelz G, Serón D, Grinyó J, Loupy A, Kuypers D, Mariat C, Clancy M, Jardine AG, Guirado L, Fellström B, O'Grady J, Pirenne J, O'Leary JG, Aluvihare V, Trunečka P, Bacarani U, Neuberger J, Soto-Gutierrez A, Geissler EK, Metzger M, Gray M. Advancing Transplantation: New Questions, New Possibilities in Kidney and Liver Transplantation. (2017) TRANSPLANTATION 101 Suppl 2S, S1-S41.

IF: 3.6780